Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEV801 in Advanced Malignancies
NCT02797795Phase 1Completed
- Sponsor
- Neovia Oncology
- Start
- Dec 2016
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NEV-801 in cancer, sponsored by Neovia Oncology. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Dec 2016; status: completed.
02
Drugs
NEV-801
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02797795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797795.